Narrative review / 2013
Clinical trials demonstrate that curcumin modulates multiple signaling molecules, is safe up to 12 g/day for 3 months, and shows promise in inflammatory diseases.
This review examines clinical trials from the past quarter century addressing the pharmacokinetics, safety, and efficacy of curcumin in humans. Promising effects were noted in patients with diverse pro-inflammatory diseases, such as cancer, cardiovascular disease, arthritis, gastrointestinal conditions, diabetes, and renal diseases. Dose-escalating studies showed curcumin is safe at doses as high as 12 g/day over 3 months. Curcumin modulates numerous human signaling molecules, including pro-inflammatory cytokines, apoptotic proteins, NF-κB, COX-2, STAT3, C-reactive protein, and triglycerides.
- Study type
- Narrative review of clinical trials
- Who was studied
- Human patients across various pro-inflammatory diseases
- What was measured
- Pharmacokinetics, safety, efficacy, and modulation of signaling molecules
THE PAPER
Therapeutic roles of curcumin: lessons learned from clinical trials.
Gupta SC, Patchva S, Aggarwal BB. AAPS J, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.